Jan 10 (Reuters) - Pacira Biosciences Inc PCRX.O:
PACIRA BIOSCIENCES: SEES DOUBLE-DIGIT COMPOUNDED ANNUAL GROWTH RATE IN PRODUCT REVENUE BY 2030
PACIRA BIOSCIENCES INC: SEES 5 PERCENT POINT GROSS MARGIN IMPROVEMENT OVER 2024 IN PROFITABILITY BY 2030
PACIRA BIOSCIENCES: PRELIM Q4 EXPAREL NET PRODUCT SALES OF $147.7 MILLION
Source text: nGNX99rV9F
Further company coverage: PCRX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.